Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis

Award Number: R01DE034377
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/08/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis - PROJECT SUMMARY/ ABSTRACT Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent aggressive cancers worldwide. Despite advances in diagnostics and treatments, the 5-year survival of HNSCC remains low (~50%). Patients with HPV-negative tumors exhibited an even worse prognosis. There is a pressing and unmet need to identify reliable molecular biomarkers for prognostic prediction in HNSCC, crucial for personalized patient care. This enables the selection of more aggressive or novel treatments like immunotherapy for high-risk patients, while also guiding treatment deintensification for those at low risk. DNA methylation (DNAme) is a key player in all major cancer hallmarks, encompassing a range of processes from tumorigenesis and cancer progression to its pivotal role in shaping the tumor-immune microenvironment and influencing drug/treatment resistance. DNAme is also known to be responsive to both genetic variations and environmental exposures, both of which are driving factors underlying the etiology and pathogenesis of HNSCC. Building upon extensive preliminary data, we hypothesize that the incorporation of non-invasive and ultrasensitive detection of circulating DNA methylation, including analysis of circulating cell-free DNA and immune cells from peripheral blood, will markedly enhance the precision of prognostic predictions in patients with HNSCC. In this R01 project, we propose to establish a dedicated clinical cohort of HNSCC named PHENEX, along with novel analytical methodologies (Aim 1) to validate, discover and optimize noninvasive liquid biopsy tests for HNSCC based on cell-free DNA methylome of plasma samples (circulating tumor panel); (Aim 2) to uncover novel DNAme biomarkers in the matched peripheral immune cells to further improve the liquid biopsy test for the prognostic biomarker discovery (circulating immune panel); and finally (Aim 3) to investigate the potential of integrating cancer-specific and immune-specific biomarkers for immunotherapy outcome prediction (PHENEX-IO). We will utilize an ultrasensitive technology developed by our team, known as cfMBD-seq, for ultra-low-input DNA methylome analysis of HNSCC plasma samples. As an integral part of our biomarker discovery process, the matched tumor tissues will also be profiled for DNAme, providing a holistic understanding of the epigenetic landscape in HNSCC. The PHENEX cohort will leverage both existing tissue samples collected from Moffitt Total Cancer Care (TCC) and established biospecimen collection workflows for prospective sample collection, aiming to create an effective and sustainable resource. This project will be undertaken by a team of investigators who have proven track record and extensive experience in head and neck oncology and epigenomic biomarker discovery. Collectively, our results are set to deliver an immediate translational impact by informing more precise therapeutic strategies and clinical management of HNSCC, ultimately improving the overall outcome for patients battling this dismal disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $712,674 )
2026	2026	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 USF MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Oral Diseases and Disorders Research	000	2	6/11/2026	NON-COMPETING CONTINUATION	$712,674
														Subtotal = $712,674

Issue Date FY: 2025 ( Subtotal = $716,123 )
2025	2025	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 USF MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Oral Diseases and Disorders Research	000	1	9/8/2025	NEW	$716,123
														Subtotal = $716,123

Grand Total All Awards = $1,428,797

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis

Award Number: R01DE034377

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/08/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer